Adeno-associated viruses (AAV) have revolutionised gene therapies as safe and effective gene shuttles. The growing demand for AAV vectors now requires an industrialised process throughout pre-clinical development that involves comprehensive monitoring from production to patient to ensure safety and efficacy of the therapeutic agent and reduce cost of goods.
Red blood cell contaminants from source material
BackgroundIsolating cells from whole blood or LRS cones carries the risk of red blood cell (RBC) contamination, which can have deleterious effects on downstream cell cultures.
AAV Gene Therapy: Monitoring Manufacturing
Sponsored PublicationsAdeno-associated viruses (AAV) have revolutionised gene therapies as safe and effective gene shuttles. The growing demand for AAV vectors now requires an industrialised process throughout pre-clinical development that involves comprehensive monitoring from production to patient to ensure safety and efficacy of the therapeutic agent and reduce cost of goods.
COVID-19 med APN01 selected to be tested in ACTIV study
Latest NewsAPEIRON Biologics’ recombinant ACE2 APN01 has been selected to participate in the US ACTIV study. ACTIV is aimed to speed up development of the best COVID-19 meds.
Hummingbird Bioscience raises $125m in Series C financing
Latest NewsDanish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
AELIX: Next stage with new CEO
AppointmentsBarcelona-based Aelix Therapeutics has appointed Dr Melanie Rolli as CEO. Her predecessor, Dr Jose Luis Cabero, had decided to step down from executive positions at Aelix
BD installs production hub in Zaraogza
Latest NewsBD will build a €165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches €300m funding
Latest NewsGerman government has launched a €300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
Recombinant silk producer AMSilk raises €29m
Latest NewsAMSilk GmbH has closed a Series C financing at €29m to accelerate and expand commercialisation of its microbially produced silk fibres.
SARS-CoV-2-antibodies may promote severe COVID-19
Latest NewsImmunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
Latest NewsInternational life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.